

Virtual Colony Count Study of the Inoculum Effect of HNP1 against *Staphylococcus aureus* ATCC 29213

Bryan Ericksen*

School of Medicine Institute of Human Virology, University of Maryland, Baltimore, Baltimore, Maryland, USA

***Corresponding Author:** Bryan Ericksen, School of Medicine Institute of Human Virology, University of Maryland, Baltimore, Baltimore, Maryland, USA.

Received: July 30, 2026; **Published:** August 13, 2026

Abstract

Background: Virtual colony count is a kinetic, 96-well turbidimetric assay that has been used since 2003 to determine the antimicrobial activity of antimicrobial peptides including the defensin HNP1. Virtual colony count results differed from traditional colony counting results in studies of the antimicrobial activity of the human cathelicidin LL-37 and related peptides. The difference could possibly have been caused by an inoculum effect.

Methods: The virtual colony count assay was conducted using inocula that varied from 1250 to 1×10^8 virtual colony forming units (CFUv) per milliliter.

Results: The virtual colony count assay demonstrated a pronounced inoculum effect of HNP1 against *Staphylococcus aureus* ATCC 29213, accompanied by biofilm formation observed in the wells of the 96 well plates at all inocula. The *S. aureus* inoculum effect was not as drastic as previously reported for *Escherichia coli*.

Conclusion: The inoculum effect is further evidence that biofilm formation is a resistance mechanism used by a variety of bacteria against antimicrobial peptides such as HNP1.

Keywords: HNP1; *Staphylococcus aureus* ATCC 29213; Virtual Colony Count (VCC)

Introduction

Staphylococcus aureus ATCC 29213 has been studied repeatedly as the representative gram positive strain in a series of publications since 2005 using the virtual colony count (VCC) antibacterial assay [1-12]. In all of these studies, HNP1 was used as the positive control peptide. Therefore, a large body of work exists with this combination of bacterial strain and antimicrobial peptide. In 2013 a side-by-side comparison of VCC and traditional colony count results was published, detailing the activity of the antimicrobial peptide LL-37 and related derivatives against several bacteria including *S. aureus* ATCC 29213 [13]. In that study, survival demonstrated by the traditional colony count method was less than virtual survival demonstrated by VCC for all peptides and bacterial strains tested. This difference could have been due to an inoculum effect. The traditional colony count inoculum was 2.5×10^4 virtual colony forming units (CFUv)/mL, whereas the standard inoculum of 5×10^5 CFUv/mL was used for the VCC assays. The inoculum was normalized across the different strains used by turbidity rather than colony forming units (CFU), as explained in the original VCC publication [1]; thus, CFUv was reported rather than CFU. This twenty-fold difference in inoculum, if responsible for the differences in measured activity, would have been the reverse of other inoculum effects reported in the literature [14], because the higher inoculum resulted in greater apparent activity.

A modified VCC procedure was used to study the inoculum effect of HNP1 against several strains of bacteria. A study of the inoculum effect of HNP1 against the standard Gram-negative strain used in the history of VCC assays, *Escherichia coli* ATCC 25922, was published in 2020, demonstrating a pronounced inoculum effect at high inocula that almost abrogated activity [15]. Similarly, the inoculum effect of HNP1 was measured against *S. aureus* ATCC 29213. The results are significant not only from the perspective of the long history of the use of this strain as the Gram-positive representative in VCC assays, but also in the further elucidation of the mechanisms of antimicrobial peptide activity and the mechanisms by which bacteria resist such activity.

Materials and Methods

The VCC procedure was modified for various inocula as previously described [15], including the use of a centrifuge to concentrate cells for the highest, 1×10^8 CFUv/mL inoculum, and the application of a strip of Parafilm to the edge of the 96-well plate to retard evaporation and allow all 96 wells to be used for the experimental portion of the assay. The change in optical density at 650 nm (ΔOD_{650}) was monitored kinetically and the time taken to reach a threshold ΔOD_{650} of 0.02 was calculated using the Visual Basic macro VCC_Calculate [15]. These threshold times were entered into complex Microsoft Excel spreadsheets to calculate virtual survival and virtual lethal doses as described in detail [15].

Results and Discussion

The inoculum effect of HNP1 against *S. aureus* ATCC 29213 (Figure 1 and Table 1) showed many of the same characteristics as the inoculum effect of HNP1 against *E. coli* ATCC 25922. There was little or no difference in activity at the lower two inocula, 1250 and 2.5×10^4 CFUv/mL, compared to the standard inoculum of 5×10^5 CFUv/mL. A noticeable inoculum effect was observed at 1×10^7 CFUv/mL, and a pronounced inoculum effect was observed at the highest inoculum of 1×10^8 CFUv/mL. Interestingly, at all inocula across a wide range of peptide concentrations, biofilms were observed in the wells of the 96-well plate [16]. This result contrasted with *E. coli*, which produced visible biofilms only at the high inocula of 1×10^7 CFUv/mL or higher. This aspect of the *S. aureus* ATCC 29213 data agrees with the history of the use of this strain in VCC assays where HNP1 was the positive control peptide, when similar biofilms were present at the standard inoculum. There was another difference between *S. aureus* and *E. coli*. *S. aureus* growth curves (ΔOD_{650} vs. time) deviated from parallel compared to the calibration controls that were not exposed to any antimicrobial agent (Figure 2). Apparently, HNP1 activity is not completely abrogated by the addition of twice-concentrated Mueller Hinton Broth (2XMHb), indicating the present of salt-tolerant HNP1 activity against *S. aureus* ATCC 29213 but not *E. coli* ATCC 25922 or any of the other strains repeatedly studied in the history of VCC assays such as *Bacillus cereus* ATCC 10876 and *Enterobacter aerogenes* ATCC 13048.




Figure 1: Inoculum effect of HNP1 against *S. aureus* ATCC 29213 as determined by the virtual colony count antimicrobial assay. Virtual survival values were calculated by comparing the threshold times of growth curves of 200 μ l batch cultures exposed to a 2-fold dilution series of HNP1 compared to control cultures of the same inoculum exposed to no defensin. Each virtual survival curve is the mean of triplicate experiments. Virtual survival values of zero could not be plotted on a logarithmic scale.

	Virtual Lethal Doses (µg/mL)			
	vLD ₅₀	vLD ₉₀	vLD ₉₉	vLD _{99.9}
1x10 ⁸ CFUv/mL	12.85 ± 4.92	29.67 ± 9.54	64.99 ± 22.83	71.87 ± 21.31
1x10 ⁷ CFUv/mL	1.89 ± 0.73	7.32 ± 2.02	20.91 ± 6.44	35.89 ± 12.02
5x10 ⁵ CFUv/mL	1.74 ± 0.80	3.57 ± 1.56	11.77 ± 4.55	23.98 ± 9.15
2.5x10 ⁴ CFUv/mL	1.88 ± 0.95	4.14 ± 2.41	12.81 ± 5.67	23.77 ± 10.33
1250 CFUv/mL	2.23 ± 1.22	3.37 ± 1.65	13.25 ± 4.71	(1)

Table 1: Virtual lethal doses of triplicate experiments of HNP1 assayed against various inocula of *S. aureus* ATCC 29213 as determined using the VCC assay. Mean values ± standard error of the mean are reported. (1) The three vLD_{99.9} values were 32 < vLD_{99.9} < 64, 14.14, and 8 < vLD_{99.9} < 16.




Figure 2: Growth curves of a VCC experiment. Solid markers are a 10-fold calibration dilution of *S. aureus* ATCC 29213 cells not exposed to defensin. Open circles are growth curves of cells exposed to 128 µg/mL (green), 64 µg/mL (lavender), 32 µg/mL (cyan), or 16 µg/mL (orange) HNP1. Growth curves were also markedly non-parallel to the calibration curves at these four HNP1 concentrations at all other inocula tested.

The inoculum effect of HNP1 against *S. aureus* ATCC 29213 reinforces other studies of biofilm formation by *S. aureus* [16], demonstrating that HNP1 promotes the formation of biofilms that are, in turn, resistant to HNP1 activity. The inoculum effect was not quite as pronounced with *S. aureus* ATCC 29213 as with *E. coli* ATCC 25922, in the sense that there was greater activity against *S. aureus* ATCC 29213 at the high inoculum of 1x10⁷ CFUv/mL and virtual survival of less than 1x10⁻¹ at both 64 and 128 µg/mL at the highest inoculum against *S. aureus* ATCC 29213. However, the presence of *S. aureus* ATCC 29213 biofilms was ubiquitous at many defensin concentrations and all inocula studied, indicating that biofilm formation is a strategy employed by this strain to resist HNP1 activity regardless of cell density. These results may explain why *S. aureus* infections are persistent in spite of the activity of human neutrophils. However, the finding that HNP1 activity was not completely abrogated by the addition of 2XMHB indicates that HNP1 is more effective against *S. aureus* in the presence of

physiological salt concentrations than it is against other bacterial strains commonly studied. The bad news for the host regarding biofilm formation may be partially ameliorated by the good news that HNP1 can slow growth rates, possibly indicating that HNP1 has a role in preventing the spread of *S. aureus* colonization to other parts of the body.

The inoculum effect against both *E. coli* and *S. aureus* is consistent with the need for a minimum HNP1 concentration in membranes to be active. This interpretation of the inoculum effect agrees with that of other authors who have discovered inoculum effects of antimicrobial peptides. The first inoculum effect of a defensin was observed in 1993, when the activity of Rabbit NP-1 was tested against *Cryptococcus neoformans* [17]. There was greater minimum inhibitory concentration (MIC) activity observed at the inoculum of 10^4 cells/mL compared to 10^5 or 10^6 . Not all studies that varied inoculum size of antimicrobial peptides resulted in an inoculum effect. The activity of omiganan was not affected by inoculum size from 10^3 - 10^7 CFU in an *ex vivo* pig skin colonization model [18]. An inoculum effect was demonstrated for Casein A and B against *E. coli* when comparing inocula of 10^1 and 10^3 cells/mL vs. a standard inoculum of 10^6 cells/mL [19]. An inoculum effect using inocula from the neighborhood of the standard inoculum of 5×10^5 cells/mL to 6×10^6 cells/mL was also demonstrated for LL-37 against *E. coli*, with increasing MIC as a function of cell density [20]. A large study of 13 antimicrobial peptides covering more than seven orders of magnitude in inoculated cell density indicated that the inoculum effect is a universal property of the activity of antimicrobial peptides, irrespective of their mechanism of action [21]. It should be noted that HNP1 could not be studied with MIC methods, because the presence of rich media contains sufficiently high salt concentration to abrogate the activity of HNP1, except for the non-parallel VCC growth curves with *S. aureus* ATCC 29213, as noted in the results section above, which would not be detectable in an overnight MIC assay. It is also noteworthy that a paradoxical data point resulted from the exposure of 128 μ g/mL HNP1 to the highest inoculum of 1×10^8 CFU/mL. This apparent decrease in activity at the highest defensin concentration could be caused by cell autoaggregation and biofilm formation in that batch culture. Although this phenomenon was observed only in one experiment at the highest cell concentration in this dataset, it occurred at other inocula in the *E. coli* dataset [15].

The mechanistic basis for the inoculum effect may involve resistance mechanisms that are more prevalent at high cell concentrations and are part of the process of biofilm formation. For example, bacterial biofilms contain extracellular polymeric substances (EPS) including nucleic acids and polysaccharides [22]. EPS may contain polymers such as capsular polysaccharides and RNA that bind and inhibit defensins [23]. However, biofilms were observed at all cell concentrations in the VCC studies of *S. aureus* ATCC 29213, indicating that this resistance mechanism is important for both dilute, predominantly planktonic cells and higher cell concentrations.

Conclusion

Regarding the original impetus to conduct the study of the inoculum effect, it is apparent that the difference in activity between VCC and traditional colony count observed in the 2013 *Biochemistry* study [13] cannot be explained by an inoculum effect. The simplest explanation of the difference is that VCC threshold time delays can be caused both by bactericidal killing and by the lag phase preceding exponential growth. Comparing calibration threshold times with traditional colony count results, lag times of approximately 60 - 90 minutes were observed. Apparently, after exposure to antimicrobial peptides such as LL-37, the survivors require some time to repair or replace damaged membranes, cell walls, or intracellular targets before entering into exponential growth. Further studies using methods such as traditional colony count and methods to study biofilms are warranted to confirm these results and elucidate the mechanistic underpinnings of the inoculum effect.

Competing Interests

No competing interests were disclosed

Grant Information

This work was funded by Peprotech, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

I thank Wuyuan Lu for providing antimicrobial peptides and helpful discussions.

Bibliography

1. Ericksen B., *et al.* "Antibacterial activity and specificity of the six human α -defensins". *Antimicrobial Agents and Chemotherapy* 49.1 (2005): 269-275.
2. Pazgier M., *et al.* "Sometimes it takes two to tango: contributions of dimerization to functions of human α -defensin HNP1 peptide". *Journal of Biological Chemistry* 287.12 (2012): 8944-8953.
3. Rajabi M., *et al.* "Functional determinants of human enteric α -defensin HD5: crucial role for hydrophobicity at dimer interface". *Journal of Biological Chemistry* 287.26 (2012): 21615-21627.
4. Wei G., *et al.* "Through the looking glass, mechanistic insights from enantiomeric human defensins". *Journal of Biological Chemistry* 284.42 (2009): 29180-29192.
5. Wei G., *et al.* "Trp-26 imparts functional versatility to human alpha-defensin HNP1". *Journal of Biological Chemistry* 285.21 (2010): 16275-16285.
6. Wu Z., *et al.* "Why is the Arg5-Glu13 salt bridge conserved in mammalian alpha-defensins?" *Journal of Biological Chemistry* 280.52 (2005): 43039-43047.
7. Wu Z., *et al.* "Impact of pro segments on the folding and function of human neutrophil alpha-defensins". *Journal of Molecular Biology* 368.2 (2007): 537-549.
8. Xie C., *et al.* "Reconstruction of the conserved beta-bulge in mammalian defensins using D-amino acids". *Journal of Biological Chemistry* 280.38 (2005): 32921-32929.
9. Xie C., *et al.* "Effects of the terminal charges in human neutrophil alpha-defensin 2 on its bactericidal and membrane activity". *Peptides* 26.12 (2005): 2377-2383.
10. Zhao L., *et al.* "Invariant gly residue is important for α -defensin folding, dimerization, and function: a case study of the human neutrophil α -defensin HNP1". *Journal of Biological Chemistry* 287.23 (2012): 18900-18912.
11. Zhao L., *et al.* "Single, double and quadruple alanine substitutions at oligomeric interfaces identify hydrophobicity as the key determinant of human neutrophil alpha defensin HNP1 function". *PLoS One* 8.11 (2013): e78937.
12. Zou G., *et al.* "Molecular determinants for the interaction of human neutrophil alpha defensin 1 with its propeptide". *Journal of Molecular Biology* 381.5 (2008): 1281-1291.
13. Pazgier M., *et al.* "Structural and functional analysis of the pro-domain of human cathelicidin LL-37". *Biochemistry* 52.9 (2013): 1547-1558.
14. Brook I. "Inoculum effect". *Reviews of Infectious Diseases* 11.3 (1989): 361-368.
15. Ericksen B., *et al.* "Virtual colony count". *WikiSci* 3.1 (2020): 3.
16. Liao C., *et al.* "Human neutrophil α -defensin HNP1 interacts with bacterial cell wall components to promote biofilm formation by *Staphylococcus aureus*". *Biofilm* 10 (2025): 100338.

17. Alcouloumre MS., *et al.* "Fungicidal properties of defensin NP-1 and activity against *Cryptococcus neoformans* in vitro". *Antimicrobial Agents and Chemotherapy* 37.12 (1993): 2628-2632.
18. Rubinchik E., *et al.* "Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonization models". *International Journal of Antimicrobial Agents* 34.5 (2009): 457-461.
19. McDonnell MJ., *et al.* "Inhibition of verocytotoxigenic *Escherichia coli* by antimicrobial peptides caseicin A and B and the factors affecting their antimicrobial activities". *International Journal of Food Microbiology* 153.3 (2012): 260-268.
20. Snoussi M., *et al.* "Heterogeneous absorption of antimicrobial peptide LL-37 in *Escherichia coli* cells enhances population survivability". *eLife* 7 (2018): e38174.
21. Loffredo MR., *et al.* "Inoculum effect of antimicrobial peptides". *Proceedings of the National Academy of Sciences of the United States of America* 118.21 (2021): e2014364118.
22. Ikuma K., *et al.* "The extracellular bastions of bacteria-a biofilm way of life". *Nature Education Knowledge* 4.2 (2013): 2.
23. Ericksen B. "Quantification of polysaccharides fixed to Gram stained slides using lactophenol cotton blue and digital image processing". *F1000Research* 4 (2015): 1.

Volume 22 Issue 9 September 2026

©All rights reserved by Bryan Ericksen.